NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).
Annual Awards Program Recognizes Top Mindful Companies, Services and Products Within the Packaged Goods Industry LOS ANGELES, June 12, 2026 /PRNewswire/ -- The 2026...
In 2026 Morvulikent has officially announced the launch of its new AI-powered trading platform, introducing a next-generation automated trading environment designed to simplify financial market participation through artificial intelligence, real-time data analysis, and intelligent automation.
SAN FRANCISCO, June 12, 2026 /PRNewswire/ -- Through Viewing China from Afar: Beyond Hollywood, produced by People's Daily Online West USA, audiences explore the ideas...
Aggressive Output. Rugged Reliability. The new series is purpose-built for SPL competition vehicles and performance-focused builds where maximum output matters most.TEMPE, Ariz., June 12,...
For a limited time, customers purchasing a select LG CineBeam projector will receive a free xboom grab speaker, creating the ultimate immersive match-night atmosphere.NEWS...
New senior moving certification program helps older adults move with greater confidence and supportINDIANAPOLIS, June 11, 2026 /PRNewswire/ -- Bekins Van Lines announces the...
Donation to Boys & Girls Clubs of America will support soccer programming, workforce development and other initiatives serving youth across Southern CaliforniaATLANTA, June 12,...
Donation to Boys & Girls Clubs of America will support soccer programming, workforce development and other initiatives serving youth across Southern CaliforniaATLANTA, June 12,...
A Whole Food Plant Protein Designed to Support Real LifePALMYRA, Wis., June 12, 2026 /PRNewswire/ -- POSSIBLE® by Standard Process® is proud to announce the...
TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss,...